NovoCure Limited Officer Compensation Adjustment

NovoCure Limited has amended the compensation of Uri Weinberg, M.D., Ph.D., a named executive officer, in connection with his appointment as Chief Medical Officer in addition to his existing role as Chief Innovation Officer. Effective April 8, 2026, Dr. Weinberg will receive a monthly salary increase of CHF 5,000 as long as he holds the Chief Medical Officer position. This increase is specifically for the additional responsibilities of the CMO role and will not affect his annual incentive payment. All other employment terms remain unchanged. The company also noted the filing of the Weinberg Letter Agreement as an exhibit.